Trials / Completed
CompletedNCT05202808
RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study
RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- RxSight, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Light Adjustable lens (LAL) and Light Delivery Device (LDD) | Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments |
| DEVICE | Control IOL | Control treatment group will receive a Control IOL |
Timeline
- Start date
- 2021-12-03
- Primary completion
- 2024-09-11
- Completion
- 2024-12-16
- First posted
- 2022-01-24
- Last updated
- 2025-04-20
- Results posted
- 2025-04-20
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05202808. Inclusion in this directory is not an endorsement.